1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Poseida, Legend/Janssen Look To Snag Celgene/Bluebird's BCMA Crown

 
• By Mandy Jackson

Poseida and Legend/Janssen aim to develop CAR-T therapies with improved efficacy and safety, and both programs delivered updates at ASH for BCMA-targeting CAR-T candidates in multiple myeloma that could challenge Celgene/bluebird's lead in this field.

T-cells attacking cancer_1200x675

While Celgene Corp. and bluebird bio Inc. have the most advanced BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapy in the clinic for the treatment of relapsed or refractory multiple myeloma, data presented at the American Society of Hematology (ASH) meeting on Dec. 3 in San Diego show that CAR-T therapies against the same target from Poseida Therapeutics Inc., partners Legend Biotech Corp. and Janssen Pharmaceutical Cos., and others are quickly gaining ground.

Early Phase I data showing strong responses in the first 12 patients treated with Celgene's and bluebird's bb21217 – the partners' next-generation CAR-T asset targeting B-cell maturation antigen (BCMA) – were presented at ASH on Dec. 2, but not for their pivotal-stage candidate bb2121. However, data for several other autologous BCMA-targeting CAR-T candidates also were presented on Dec 3, including results from 44 patients treated with Celgene's JCARH125, the BCMA-targeting CAR-T program it bought in the $9bn acquisition of Juno Therapeutics Inc. earlier this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.